Nephrogenic systemic fibrosis (NSF) is an emerging sclerodermalike disease that affects almost exclusively patients undergoing hemodialysis for end-stage renal disease (ESRD). Increasing evidence indicates that NSF is induced by gadolinium-based contrast agents commonly used in magnetic resonance imaging (MRI). Nephrogenic systemic fibrosis may result in significant morbidity and mortality, and a high proportion of patients end up in wheelchairs or become bedridden because of their progressive joint contractures. To date, no consistently effective therapy is available for NSF. Phototherapy with UV-A1, frequently used for other sclerotic skin diseases, has been reported to have beneficial effects in NSF.1 We herein report our results from 3 patients treated with UV-A1 phototherapy (Table).
Kreuter A, Gambichler T, Weiner SM, Schieren G. Limited Effects of UV-A1 Phototherapy in 3 Patients With Nephrogenic Systemic Fibrosis. Arch Dermatol. 2008;144(11):1527–1529. doi:10.1001/archderm.144.11.1527
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: